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Pediatria, Ginecologia i Medicina Preventiva. Universitat Autònoma de Barcelona, Spain, 4 Departament de Salut Pública, Universitat de Barcelona, Barcelona, Spain,
5 Departament de Ciencies Basiques, Universitat Internacional de Catalunya, Barcelona, Spain, 6 Infectious Diseases Service. Hospital Clinic Universitari – IDIBAPS of
Barcelona, Barcelona, Spain
Abstract
Background: Tuberculosis (TB) recurrence can be due to reinfection or relapse. The contribution of each to TB incidence and
the factors associated with recurrence are not well known. Effectiveness of TB control programs is assessed in part by
recurrence rates. The aim of this study was to establish the recurrence rate of TB in Barcelona, the associated risk factors and
the role of reinfection.
Methods: A population-based retrospective longitudinal study was performed in Barcelona, Spain. TB patients with positive
culture results who completed treatment between Jan 1st, 2003 and Dec 31st, 2006 were followed-up until December 31st,
2009 by the TB Control Program. The incidence rate of recurrence was calculated per person-year of follow-up (py). Kaplan-
Meier and Cox regression methods were used for the survival analysis by calculating the hazard ratio (HR) with 95%
confidence intervals (CI).
Results: Of the 1,823 TB cases identified, 971 fulfilled the inclusion criteria and 13 (1.3%) had recurrent TB. The recurrence
rate was 341 cases per 100,000 py, 13 times higher than the TB incidence of the general population. Likelihood of TB
recurrence at the 1st, 3rd and 5th year of follow-up was 0.1%, 1.4% and 1.6%, respectively. Factors associated with
recurrence were HIV infection (HR: 4.7, CI: 1.4–15.7), living in the inner city district (HR: 3.9, CI: 1.3–11.8) and history of TB
treatment (HR: 5.2, CI: 1.7–16.2). Genotyping results of recurrent cases were available for 6 patients (3 reinfections and 3
relapses).
Conclusion: The rate of TB recurrence in Barcelona is low and most episodes occur within the first three years. Patients at
higher risk of recurrence are co-infected with HIV, living in neighborhoods with high TB incidence or with a history of TB
treatment. When available, genotyping results help determine whether the recurrence is due to reinfection or relapse.
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Introduction
Recurrence of tuberculosis (TB) can be due to a regrowth of the
same strain of Mycobacterium tuberculosis that caused the previous TB
episode, known as relapse, or reinfection through a different strain.
The data reported suggests that recurrence rate is low in countries
with a low TB incidence and mainly caused by relapse of a
previously cured TB episode [1–3]. The recurrence rate in
countries of high TB incidence is elevated and reinfection is the
principal cause [4], especially in the presence of high prevalence of
coexisting human immunodeficiency virus (HIV) [5]. Studies
carried out in countries of medium incidence suggest that relapse
more commonly causes recurrence, although the rate of reinfec-
tion could still play an important role [6,7]. Therefore, the relative
contribution of recurrent TB on the overall annual TB incidence
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and the influence of relapse or reinfection is likely to vary
depending on epidemiological features of the area [1–8].
Information about the epidemiological and microbiological
characteristics of recurrent TB is an important issue for public
health programs to ensure appropriate health control strategies
[9]. Moreover, recurrence rates can be used to assess the
effectiveness of TB control programs. Because many large cities
in developed countries have recently experienced important
demographic changes, related HIV infection and from high-
burdened TB countries knowledge of the characteristics and
outcomes of TB cases in each population is even more necessary to
direct local public health programs. Barcelona had a median TB
incidence of 26.3 per 100,000 person-years of follow-up (py)
during 2003–2008 but over 100 in some neighborhoods such as
the inner-city district, where a significant proportion of residents
have low socioeconomic status [10].
The relative contribution of TB reinfection and relapse to the
overall incidence and the risk factors associated with recurrent TB
are not well-known. This longitudinal study aims to assess the
incidence of recurrent TB in a retrospective, large cohort of TB




Demographic and clinical data was obtained from the
epidemiological questionnaire used by the Barcelona TB Preven-
tion and Control Program (TBPCP). All data for the study was
recorded and analysed anonymously. The data was collected on a
routine basis as per the National Tuberculosis Plan approved by
the Spanish Ministry of Health and the analysis was carried out
retrospectively. Therefore no informed consent was required.
Ethics approval was obtained from Clinical Research Ethics
Committee of the Institut Municipal d’Assistència Sanitària
(IMAS). All data was treated in a strictly confidential manner
according to the ethical principles of the Helsinki Declaration of
1964 revised by the World Medical Organization in Edinburgh,
2000 and the Organic Law 15/1999 of Data Protection in Spain.
Setting
The study was conducted in Barcelona (Catalonia, Spain), an
urban area of 100.4 square km, whose census population was
1,508,805 inhabitants in 2008 [11]. The TBPCP has been
operating for over 25 years.
Study design and population
This retrospective population-based cohort study included
pulmonary, extrapulmonary, and pulmonary-extrapulmonary
Figure 1. The flow chart of tuberculosis patient selection and evolution. Barcelona 2003–2009.
doi:10.1371/journal.pone.0064898.g001
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TB patients detected by the TBPCP with at least one culture result
positive for M. tuberculosis, who started treatment between January
1st, 2003 and December 31st, 2006 who lived in Barcelona during
the study period. National and international TB treatment
guidelines were followed but patients were not required to
complete therapy within 2003–2006. TB cases who completed
the entire treatment course according to the recommendations of
the European Treatment Outcome Definition were selected and
followed to determine the recurrence rate and associated risk
factors [12–15]. Patients who did not complete therapy were
excluded. The follow-up was closed on December 31st, 2009. At
that date, all cases were classified either as recurrence or censured.
The censorship date for each patient was the last day the patient
was followed. Censured cases included patients who remained
cured, had died, moved away or who were not found (lost to
follow-up) at the end of the follow-up period.
Definitions
A definite TB case was identified using the recommended
international definition: a patient was considered to have TB if
their culture was positive for M. tuberculosis complex. All patients
who completed TB treatment, regardless of negative culture
conversion, were considered cured., TB recurrence was defined
according to the CDC and the Spanish recommendations for TB
surveillance [16–17] as any new clinical and/or microbiological
TB diagnosis in a patient who had completed anti-TB treatment
and had been TB disease-free for at least one year since treatment
completion [16,17]. TB disease within 12 consecutive months after
the treatment completion was considered the same TB episode.
The follow-up time was calculated in reference to the time elapsed
since the end of TB treatment until recurrence, death, moved
away (transferred), or the end of the study.
Variables and information sources
All data was obtained from the epidemiological surveys
performed by public health nurses on TB cases reported to the
Barcelona TBPCP [8]. The Epidemiology Service collects
information on all TB and AIDS cases voluntarily notified by
physicians and also performs active surveillance for undeclared or
subnotified cases coming from microbiology services, hospital
discharge reports, city mortality and social service registries. We
reviewed the following socio-demographic variables: age, sex,
Table 1. Baseline clinical and socio-demographic characteristics of the cohort and recurrence of tuberculosis. Barcelona, 2003–
2006.
Cohort
N = 971 (%)
Recurrence
n = 13 (%)
No recurrence (Censure)
n = 958 (%) p-value*
Age years, median
(10–90 percentile)













































































































*Chi-square test (Fisher’s exact test when an expected value is less than five). Mann-Whitney test was used for age.
1IDU: intravenous drug use. 2HIV: human immunodeficiency virus. 3MDR TB: multi-drug resistant tuberculosis.
doi:10.1371/journal.pone.0064898.t001
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country of birth (Spain or foreign-born), city district of residence
(inner-city or other), homelessness, prison history, smoking,
alcohol abuse and injecting drug use (IDU). Clinical variables
included HIV infection, TB recurrence, and type of TB
(pulmonary or/and extrapulmonary forms). Microbiological and
treatment variables included smear test results, history of TB
treatment, and type and extent of resistance, if any (none, primary
or secondary, multi-drug resistance, MDR). MDR was defined as
resistant to at least isoniazid and rifampin.
After disease confirmation, study subjects were followed to
identify any recurrent TB episode reported to the Barcelona or
Catalonia regional programs and/or the date of transfer to
another TB Program and to verify their vital status at the end of
the study period. Hospital records, primary care records, the city
census and mortality registry, and the drug abuse program in
Barcelona were reviewed to minimize the number of patients lost
to follow-up and avoid duplicate information. At the end of the
study, patients were considered lost to follow-up when vital status
or data about leaving the city were unavailable.
Laboratory Methods
M. tuberculosis was identified by conventional standardized
methods [18] and molecular study of the strains was centralized
in one of the six participating centers. Genotyping was performed
using the proper standardized protocols for restriction fragment
length polymorphism (RFLP)-IS6110 and the IS6110 fingerprint
patterns were analyzed with whole-band analyzer software
(version 3.2.2; BioImage, Inc., Ann Arbor, MI) by the unweight-
ed-pair group method with arithmetic means and Dice coefficient.
Isolates were grouped into the same RFLP cluster when they
showed identical RFLP patterns (equal numbers of IS6110 bands
at identical positions). All isolates with 6 or less IS6110 bands
belonging to an RFLP cluster underwent analysis of a second
marker (MIRU 12 or Spoligotyping) [19–23].
Statistical analysis
A descriptive analysis of the cohort was performed with the
median and 10–90 percentiles calculated for quantitative vari-
ables. Frequency tables and Pearson’s chi-squared test were used
for categorical variables, as well as two-sided Fisher’s Exact tests
when expected frequencies were less than five. Non-parametric
continuous variables were analyzed using the Mann-Whitney U-
test.
The incidence of recurrence in cases py of follow-up was
calculated for the general population and for relevant subgroups
(IDU, HIV, immigrants, MDR-TB patients, inner-city district
residence and history of TB treatment). The rate ratio was
calculated to compare the recurrence rate and the median
incidence rate of general population during the study period.
The denominator consisted of the sum of the follow-up periods
from the date of TB completion until recurrence, death,
transferred, the last day of follow-up, or the end of the study.
Recurrence curves were estimated using the Kaplan–Meier
method. Subgroups of interest were compared using the log rank
test, univariate and multivariate analyses were performed using
Cox’s proportional hazards model and the variables which showed
an association (p-value ,0.10) or of epidemiological interest at the
univariate level were included in the multivariate analysis. Hazard
Ratios (HR) were used as the measure of association with 95%
confidence intervals (95%CI) were calculated and a stepwise
forward inclusion approach was used. The proportionality of risks
in the Cox model was verified using a Shoenfeld residuals plot and
test results were considered to be statistically significant when the
resulting p-value was ,0.05. All the analyses were performed
using SPSS 18.0 and the statistical package R (The R foundation
for Statistical computing), version 2.9.0.
Results
Cohort selection
Figure 1 shows the cohort selection flow-chart. A total of 1,823
TB cases were identified during the study period, of which 971
fulfilled the inclusion criteria and constituted the study cohort.
Cohort description
Table 1 describes the characteristics of the cohort. The median
age in the cohort was 38 (Range: 22–70) years and 65% of the
subjects were men. Information on drug susceptibility testing
(DST) was not available for 194 (20%) patients. A subanalysis of
this group didn’t show differences with the rest of the cohort
except for immigrant status occurred more frequently among those
with available DST results. Nine (1%) isolations of MDR-TB were
identified and none had extensively drug-resistant TB (XDR TB:
Figure 2. Kaplan-Meier curves of the risk of tuberculosis recurrence among patients with HIV infection, history of TB treatment and
who live in the inner-city district. Barcelona 2003–2009.
doi:10.1371/journal.pone.0064898.g002




pŷ Recurence rate (105 py) Rate ratio* (CI95%)
Overall 13 3814 341 13.1 (12.1–14.8)
IDU1 2 178 1124 43.2 (22.0–64.4)
HIV2 4 268 1493 57.4 (43.3–71.5)
Immigrant 4 1302 307 11.8 (8.9–14.7)
Inner-city district 6 614 977 37.6 (31.5–43.7)
MDR-TB3 1 24 4167 160.3 (3.2–317.4)
History of TB treatment 5 292 1712 65.9 (53.0–74.8)
*Ratio between recurrence rate and the median incidence rate in the general population during the study period (266105); ˆpy: person-years of follow–up.
1IDU: intravenous drug use. 2HIV: human immunodeficiency virus. 3MDR TB: multi-drug resistant tuberculosis.
doi:10.1371/journal.pone.0064898.t002
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resistant to first and second-line TB drugs). Of the 971 cases, 84
(8.7%) history of TB treatment prior to study inclusion. Of these, 5
(6%) had a new episode (recurrence) of TB during the follow-up
period. Also of these 84 cases, 51 (60.7%) correctly completed
treatment, 22 (26.2%) did not correctly complete treatment and
treatment completion was unknown for 9 (13.1%) cases.
The median follow-up time was 4 years (2.2–5.9). At the end of
the study period, 824 (84.9%) cases correctly completed treatment,
84 (8.6%) died, 27 (2.8%) moved and 24 (2.4%) were lost to follow-
up (Figure 1). TB recurrence occurred in 13 (1.3%) cases, with a
median time (rank) of follow-up of 2.2 (1–4.5) years before
recurrence.
Recurrence rates
The incidence of recurrent TB episodes in the cohort was 341
per 100,000 py. The likelihood of TB recurrence at the 1st, 3rd
and 5th year of follow-up was 0.1%, 1.4% and 1.6%, respectively.
The incidence rate was higher among patients with HIV
coinfection, those living in the inner-city district and in patients
with history of TB treatment. The recurrence rate among IDU
patients, HIV infected patients and MDR-TB patients were 1,123,
1,492, and 4,166 per 100,000 py, respectively. Recurrence among
immigrants was 307 per 100,000 py and among patients with a
history of TB treatment was 1,712 per 100,000 py (Table 2 and
Figure 2).
Factors associated with recurrence
The following factors were significantly associated with recur-
rence on a univariate level: living in the inner-city district, alcohol
abuse, IDU, HIV coinfection, history of TB treatment, and MDR-
TB infection. Living in the inner-city district (HR: 3.9, CI 1.3–
11.8, p = 0.02), HIV infection (HR: 4.7; CI 1.4–15.7, p = 0.02) and
history of TB treatment (HR: 5.1, CI 1.6–16.2, p,0.01) were
identified as independent factors on a univariate level with
increased risk for recurrence (Table 3).
Reinfection and Relapse
The molecular study of recurrences was available for 6 of 13
cases. Of these, 3 were reinfections and 3 were relapses. The
remaining 7 cases had negative or unavailable TB culture
(Figure 1). Relapse was found in two patients with cavitary
pulmonary TB who had received six months of anti-TB treatment
and one was HIV-positive. The other relapse occurred in a patient
undergoing immunosupressive treatment and received eight
months of anti-TB treatment. Reinfection was found in a non-
Spanish patient who lived in the inner-city, a Spanish-born patient
















































































*Hazard ratio (HR) adjusted by sex, age and other risk factors. 95% CI: 95% confidence interval. 1IDU: intravenous drug user. 2HIV: human immunodeficiency virus. 3MDR
TB: multi-drug resistant tuberculosis.
doi:10.1371/journal.pone.0064898.t003
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with diabetes, and a Spanish patient with history of TB treatment.
None of the reinfected cases were HIV-positive nor IDU.
Discussion
The overall incidence of recurrent TB in the study was 341 per
100,000 py among patients who completed TB therapy and were
considered cured during the study period. Patients who lived in the
inner-city district, were coinfected with HIV or had a history of
TB treatment had a higher risk for recurrence. Most of the
recurrences occurred during the first three years of the study.
A systematic review of prospective cohort studies and
randomised clinical trials performed in the 1990s by Panjabi
et al. [24] estimated a median recurrence rate of 1,780 per 100,00
py (range 1000–4000) in low incidence countries at 12 months
post treatment completion, which is more than five times higher
than that observed in our study. Crofts et al. [25] recently
investigated recurrences in England and Wales from 1998–2005
and found a recurrence incidence of 660 per 100,000 py among
culture-confirmed pulmonary TB cases who completed treatment;
TB incidence in the general population was 13 cases per 100,000
py in 2007. Likewise, Dobler et al. [26] reported an incidence of
recurrence of 71 per 100,000 py among culture positive patients
who had completed treatment in New South Wales, Australia
between 1994–2006 (TB incidence in the general population was
6.5 per 100,000 py in 2005). Because the median incidence of TB
in Barcelona during the study period of 26.3 per 100,000 py is two
to four times the incidence in the studies mentioned above, we
conclude that Barcelona currently has a low recurrent TB rate
given the overall TB incidence.
We also found a recurrence rate 13 times higher than the TB
incidence of the general population, suggesting that TB is more
frequent in persons who have had a history of TB treatment. This
has already been described in other studies [8,25,26]. Our findings
also revealed that recurrences do not occur homogeneously among
the population. For example, the rate of recurrence among the
HIV-infected population was 50 times higher than the incidence
of the general population. Physicians should be aware that a
history of TB treatment increases the risk of recurrence and that
the risk also varies according to the patient profile.
Of the factors determined to be predictive of recurrence, HIV-
infection has been previously identified in countries of high and
low TB incidence, such as South Africa, China, Spain, Australia,
USA, England and Wales [3,5,24–33]. Among the HIV-infected
patients, most recurrences after successful TB treatment are due to
endogenous reactivation, probably because of exposure to another
strain in low incidence areas is less likely than relapse [18,31]. As
commented by Pettit et al. [18], the higher rate of reinfection
among HIV-infected patients may be related to increase in
exposure in high incidence areas and subsequent increased risk for
disease progression. In our study, only one strain was identified
and the rest were not available for the other HIV-infected cases.
The rate of relapse found in our study was consistent with that
reported in areas with low TB incidence [1,3,32–34].
Microbiological data was available for three of the six cases of
recurrence that occurred in the inner-city district: two were
relapses and one was reinfection. The higher risk for persons who
live in the inner-city district, where the TB incidence rate is higher
than 100 cases per 100,000 py, could be explained by increased
contact between individuals due to overcrowding and poor living
conditions. Because of this greater incidence observed in the inner-
city, we would expect exogenous reinfection to be the principal
cause of recurrence, as described in previous studies, [4,5,27].
We also found that individuals who have experienced one or
more previous TB episode have an increased risk of recurrence,
even after treatment completion and cure as of inclusion for the
present study. This risk factor was previously identified in a study
conducted in South Africa [28], but in association with patients
who had defaulted therapy, not who completed treatment.
Moreover, the study conducted by Sonnenber et al. [5] among
HIV-negative patients showed that the risk of TB recurrence was
higher in patients with a history of TB treatment compared to no
history of TB treatment. HIV infection was associated with a
fivefold higher risk of recurrence in our study, suggesting
decreased immunity against TB among this subgroup.
A previous study performed in Barcelona found that IDU cases,
immigrants and males were independently related to TB
recurrence [8]. These factors were not found to be associated
with recurrence in the present study, probably due to the
incorporation of directly observed therapy (DOT) to the metha-
done maintenance program and the role of community health
workers for follow-up and contact tracing of immigrants [35]. The
lower recurrence rate in this study of 341 cases per 100,000 py
compared to 530 cases per 100,000 py among the previous 1995–
1997 cohort of could also be due to the extension and free access
to highly active antiretroviral therapy (HAART) in Spain since
1996 [8].
Few studies performed in medium incidence countries analyze
such a large number of TB cases with a completed therapy in a
population-based epidemiological study. However, our study has
some weaknesses. First, the number of recurrent TB cases in the
study is low and the number of cases without genotyping results is
high due to the negative cultures or missing isolates. Second, 23
persons, 2% of the cohort, were lost to follow-up. Most of the lost
cases belonged to subgroups with higher risk for recurrence, thus
our recurrence rate might be underestimated. However, given the
relatively small size of the missing group, it should not have a
significant influence on the risk factors found to be associated with
recurrence in our study. The recurrence rate could also be
underestimated if recurrence occurred outside of Catalonia among
patients who migrated during the study period, although analyses
do not reveal any differences in characteristics compared to the
general cohort. Also, data regarding completion of treatment for a
‘‘history of TB treatment’’ could not be available for some
patients. Finally, the lack of information about reinfection from the
same strain could cause some cases of reinfection to be deemed
relapses. As seen in other epidemiological studies, CD4 cell count
and HAART were not reported and could act as confounders
among HIV-infected patients and comparisons between our
cohort and the general population were not adjusted by age and
sex.
In conclusion, our study shows that TB recurrence in Barcelona
is low and patients with higher risk of recurrence are those with
HIV infection, who reside in the inner-city district, or had a
history of TB. This is the first study to our knowledge which found
a history of TB treatment as a risk factor for a new TB episode
independent of where the patient lives or an immunocompromised
status. Further studies focused on this subgroup are required and
physicians should be aware that a patient with a history of TB
treatment is at higher risk for recurrence, even when therapy has
been completed correctly and patient is considered cured.
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Tuberculosis recurrence and its associated risk factors among successfully treated
patients. J Epidemiol Community Health. 63: 799–804.
9. Fine P, Small P (1999) Exogenous reinfection in tuberculosis. N Engl J Med
16:1226–28.
10. Orcau A, Rius C, Garcia de Olalla P, Caylà JA (2010) La tuberculosis a
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